Pazopanib for progressive desmoid tumours: children, persistant effects, and cost

Lancet Oncol. 2019 Oct;20(10):e555. doi: 10.1016/S1470-2045(19)30543-1. Epub 2019 Sep 30.

Authors

Yoshihiro Nishida¹, Tomohisa Sakai², Hiroshi Koike², Kan Ito²

Affiliations

¹ Department of Rehabilitation Medicine, Nagoya University Hospital, Nagoya 4668550, Japan; Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya 4668550, Japan. Electronic address: ynishida@med.nagoya-u.ac.jp.
² Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya 4668550, Japan.

PMID: 31578997
DOI: 10.1016/S1470-2045(19)30543-1

No abstract available

Publication types

Letter
Comment

MeSH terms

Adult
Child
Drug Therapy, Combination
Fibromatosis, Aggressive*
Humans
Indazoles
Methotrexate
Pyrimidines
Sulfonamides
Vinblastine

Substances

Indazoles
Pyrimidines
Sulfonamides
Vinblastine
pazopanib
Methotrexate